{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:47:42Z","timestamp":1791985662336,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme UK Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ygyno.2025.04.580","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T09:11:53Z","timestamp":1745831513000},"page":"74-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and\/or BRCA2 mutation: Final overall survival results from the OPINION trial"],"prefix":"10.1016","volume":"197","author":[{"given":"Andr\u00e9s","family":"Poveda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Elstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Weberpals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bjurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sikorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Madry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jesus","family":"Rubio P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"\u00d6zg\u00f6ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Barnicle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"\u0160kof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.04.580_bb0005","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0010","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121979119","article-title":"Inhibitors of PARP: number crunching and structure gazing","volume":"119","author":"Rudolph","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0015","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0020","author":"European Medicines Agency"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0025","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0030","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0035","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0040","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/cncr.33517","article-title":"Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: a meta-analysis","volume":"127","author":"Lee","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0045","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0050","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0055","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0060","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2021.12.025","article-title":"Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1\/BRCA2 mutation: OPINION primary analysis","volume":"164","author":"Poveda","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0065","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0070","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0075","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0080","doi-asserted-by":"crossref","first-page":"S738","DOI":"10.1016\/j.annonc.2021.08.1182","article-title":"740P Olaparib maintenance monotherapy for non-germline BRCA1\/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): exploratory biomarker analyses of the phase IIIb OPINION study","volume":"32","author":"Lindemann","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0085","author":"AstraZeneca"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0095","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2025.04.580_bb0100","doi-asserted-by":"crossref","first-page":"A226","DOI":"10.1136\/ijgc-2022-ESGO.488","article-title":"2022-RA-249-ESGO: overall survival results from ARIEL3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","volume":"32","author":"Coleman","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0105","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O'Malley","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0110","author":"Clovis Oncology"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0115","unstructured":"GSK, GSK Provides an Update on Zejula (Niraparib) US Prescribing Information [Press Release]. Issued 11 November 2022. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-an-update-on-zejula-niraparib-us-prescribing-information\/ (accessed 23 April 2025)."},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2025.04.580_bb0120","doi-asserted-by":"crossref","first-page":"A15","DOI":"10.1136\/ijgc-2023-ESGO.22","article-title":"#161\u00a0final overall survival and long-term safety in the ENGOT-OV16\/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer","volume":"33","author":"Mirza","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0125","author":"AstraZeneca"},{"issue":"Suppl. 16","key":"10.1016\/j.ygyno.2025.04.580_bb0130","article-title":"Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: overall survival (OS) results from the ORZORA study","volume":"40","author":"Pignata","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0135","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1470-2045(20)30218-7","article-title":"Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial","volume":"21","author":"Blagden","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.04.580_bb0140","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.10630","article-title":"Changing patient perceptions of the side effects of cancer chemotherapy","volume":"95","author":"Carelle","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0145","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/ijgc-2021-003142","article-title":"Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the gynecologic cancer InterGroup-symptom benefit study","volume":"32","author":"Lee","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.04.580_bb0150","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:06:48Z","timestamp":1791983208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"alternative-id":["S0090825825008066"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.580","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and\/or BRCA2 mutation: Final overall survival results from the OPINION trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}